Mutant huntingtin represses CBP, but not p300, by binding and protein degradation

被引:34
作者
Cong, SY
Pepers, BA
Evert, BO
Rubinsztein, DC
Roos, RAC
van Ommen, GJB
Dorsman, JC
机构
[1] Leiden Univ, Ctr Med, CBG Ctr Human & Clin Genet, NL-2333 AL Leiden, Netherlands
[2] Leiden Univ, Ctr Med, Dept Neurol, Leiden, Netherlands
[3] China Med Univ, Affiliated Hosp 2, Dept Neurol, Shenyang, Peoples R China
[4] Univ Bonn, Dept Neurol, D-5300 Bonn, Germany
[5] Cambridge Inst Med Res, Dept Med Genet, Cambridge, England
[6] Ctr Med Syst Biol, Leiden, Netherlands
[7] Ctr Med Syst Biol, Amsterdam, Netherlands
[8] Ctr Med Syst Biol, Rotterdam, Netherlands
[9] Vrije Univ Amsterdam, Ctr Med, NL-1081 HV Amsterdam, Netherlands
关键词
D O I
10.1016/j.mcn.2005.05.003
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Huntington's disease can be used as a model to study neurodegenerative disorders caused by aggregation-prone proteins. It has been proposed that the entrapment of transcription factors in aggregates plays an important role in pathogenesis. We now report that the transcriptional activity of CBP is already repressed in the early time points by soluble mutant huntingtin, whereas the histone acetylase activity of CBP/p300 is gradually diminished over time. Mutant huntingtin bound much stronger to CBP than normal huntingtin, possibly contributing to repression. Especially at the later time points, CBP protein level was gradually reduced via the proteasome pathway. In sharp contrast, p300 was unaffected by mutant huntingtin. This selective degradation of CBP was absent in spinocerebellar ataxia 3. Thus, mutant huntingtin specifically affects CBP and not p300 both at the early and later time points, via multiple mechanisms. In addition to the reduction of CBP, also the altered ratio of these closely related histone acetyltransferases may affect chromatin structure and transcription and thus contribute to neurodegeneration. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:12 / 23
页数:12
相关论文
共 50 条
[21]   The important role of the histone acetyltransferases p300/CBP in cancer and the promising anticancer effects of p300/CBP inhibitors [J].
Wu, Xin ;
Zhang, Xin ;
Tang, Shaoshan ;
Wang, Yao .
CELL BIOLOGY AND TOXICOLOGY, 2025, 41 (01)
[22]   The structural basis of protein acetylation by the p300/CBP transcriptional coactivator [J].
Xin Liu ;
Ling Wang ;
Kehao Zhao ;
Paul R. Thompson ;
Yousang Hwang ;
Ronen Marmorstein ;
Philip A. Cole .
Nature, 2008, 451 :846-850
[23]   The structural basis of protein acetylation by the p300/CBP transcriptional coactivator [J].
Liu, Xin ;
Wang, Ling ;
Zhao, Kehao ;
Thompson, Paul R. ;
Hwang, Yousang ;
Marmorstein, Ronen ;
Cole, Philip A. .
NATURE, 2008, 451 (7180) :846-850
[24]   p300/CBP keeps chromatin silent [J].
Wrighton, Katharine H. .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2022, 29 (11) :1039-1039
[25]   p300 and CBP: Partners for life and death [J].
Giordano, A ;
Avantaggiati, ML .
JOURNAL OF CELLULAR PHYSIOLOGY, 1999, 181 (02) :218-230
[26]   CBP/p300 BromodomainMediates Amyloid Formation [J].
Liao, Daiqing .
CELL CHEMICAL BIOLOGY, 2017, 24 (02) :128-129
[27]   Viral replication and the coactivators p300 and CBP [J].
Hottiger, MO ;
Nabel, GJ .
TRENDS IN MICROBIOLOGY, 2000, 8 (12) :560-565
[28]   Selective inhibition of CBP/p300 HAT [J].
Sarli, Vasiliki ;
Giannis, Athanassios .
CHEMISTRY & BIOLOGY, 2007, 14 (06) :605-606
[29]   CBP and p300: HATs for different occasions [J].
Kalkhoven, E .
BIOCHEMICAL PHARMACOLOGY, 2004, 68 (06) :1145-1155
[30]   p300/CBP keeps chromatin silent [J].
Katharine H. Wrighton .
Nature Structural & Molecular Biology, 2022, 29 :1039-1039